NasdaqGS:RPRXPharmaceuticals
Does Amgen’s Imdelltra Royalty Acquisition Reshape the Long-Term Thesis for Royalty Pharma (RPRX)?
Royalty Pharma recently acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for US$885 million upfront, with the opportunity to expand the stake further for up to US$65 million within the next year.
This agreement gives Royalty Pharma exposure to a first-in-class oncology therapy that was FDA-approved in 2024 and is projected to achieve multi-billion dollar annual sales over time.
We’ll explore how this acquisition of a major oncology royalty stream could influence Royalty...